Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI study of KW-6356 with Clarithromycin or Rifampicin
NCT04070495Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Aug 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sipagladenant in Parkinson's disease (PD) (2 arms), sponsored by Kyowa Kirin. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Time t. Started Aug 2019; status: completed.
02
Drugs
sipagladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04070495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04070495.